Markku Jalkanen Sells 600,000 Shares of Faron Pharmaceuticals Oy (LON:FARN) Stock

Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) insider Markku Jalkanen sold 600,000 shares of Faron Pharmaceuticals Oy stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of GBX 310 ($4.19), for a total value of £1,860,000 ($2,516,233.77).

Faron Pharmaceuticals Oy Trading Up 1.9%

Shares of LON FARN traded up GBX 4 ($0.05) during trading hours on Friday, hitting GBX 219 ($2.96). The company's stock had a trading volume of 35,058 shares, compared to its average volume of 44,119. The company has a debt-to-equity ratio of 922.55, a quick ratio of 1.09 and a current ratio of 1.45. The stock has a market cap of £294.01 million, a price-to-earnings ratio of -5.86 and a beta of 0.36. Faron Pharmaceuticals Oy has a 12 month low of GBX 85 ($1.15) and a 12 month high of GBX 270 ($3.65). The business has a 50-day simple moving average of GBX 219.23 and a 200-day simple moving average of GBX 193.22.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.